I was wrong about Bavi’s advancing to phase-3 in NSCLC. Are you happy now?
The salient point, however, is that starting a phase-3 trial doesn’t imply that Bavituximab is a good drug or even that the FDA thinks it is; all it means is that FDA doesn’t think the drug is unsafe.
(By the way, what happened to the Breakthrough Therapy designation that PPHM longs said the FDA would bestow on Bavi?)
The phase-3 NSCLC trial—sans partner—will have long odds to complete enrollment in a timely fashion. There are a lot of exciting drugs in clinical development for NSCLC right now, and Bavi is far down on the list, IMO.
All told, I think today is good shorting opportunity for those who can get borrowed shares.
Market Data 
Markets 
AI
